Harmony Biosciences Holdings Inc HRMY

NAS: HRMY | ISIN: US4131971040   21:48
29,71 USD (+2,34%)
(+2,34%)   21:48
Grafiek Harmony Biosciences Holdings Inc Grafiek Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc in het nieuws

30 april 2024 · Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets · Persbericht

16 april 2024 · Harmony Biosciences To Report First Quarter 2024 Financial Results On April 30, 2024 · Persbericht

11 april 2024 · Harmony Biosciences Announces Exclusive Agreement To Develop And Commercialize Tpm-1116, A Highly Potent And Selective Oral Orexin-2 Receptor Agonist · Persbericht

3 april 2024 · Harmony Biosciences Initiates Global Phase 3 Registrational Trial (Tempo Study) Of Pitolisant In Patients With Prader-Willi Syndrome · Persbericht

26 maart 2024 · Harmony Biosciences To Participate In 23Rd Annual Needham Virtual Healthcare Conference · Persbericht

28 februari 2024 · Harmony Biosciences To Participate In Upcoming Investor Conferences · Persbericht

21 februari 2024 · U.s. Food And Drug Administration Grants Priority Review To Harmony Biosciences' Application For Wakix® (Pitolisant) In Pediatric Narcolepsy · Persbericht

20 februari 2024 · Harmony Biosciences Receives U.s. Food And Drug Administration Orphan Drug Designation For Pitolisant In Prader-Willi Syndrome · Persbericht

8 februari 2024 · Harmony Biosciences To Report Fourth Quarter And Full Year 2023 Financial Results On February 22, 2024 · Persbericht

8 januari 2024 · Harmony Biosciences Preliminary Unaudited Fourth Quarter And Full Year 2023 Net Product Revenue Increases More Than 30 Percent; Provides 2024 Net Product Revenue Guidance · Persbericht

Profiel Harmony Biosciences Holdings Inc

Farmaceutica
Gezondheidstechnologie
Medicinale en botanische productie
Productie

Werknemers: 221

Aandelen Harmony Biosciences Holdings Inc

Beurswaarde: 1,65 miljard USD

Effecten: 56,79 miljoen

Winst per aandeel (12 maand):  PLUS

Koers-winstverhouding:  PLUS

Beta: 1,13

Mijn selecties